| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 1 security · passive | ||||||
|
Neuropace, Inc.
13G/A
NPCE · 641288105
|
8.9% |
11/7/2025
Event 9/30/2025
|
||||
| Soleus Private Equity Fund I, L.P. | 0.9% | |||||
| Soleus Private Equity GP I, LLC | 0.9% | |||||
| Soleus PE GP I, LLC | 0.9% | |||||
| Soleus Capital Master Fund, L.P. | 7.9% | |||||
| Soleus Capital, LLC | 7.9% | |||||
| Soleus Capital Group, LLC | 7.9% | |||||
| Soleus Capital Management, L.P. | 8.9% | |||||
| Soleus GP, LLC | 8.9% | |||||
| Guy Levy | 8.9% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.